A new regulatory review is casting doubts on whether Pfizer can succeed in a long-running quest to dial back some of the neuropsychiatric warnings on its Chantix smoking cessation pill.

Smoking cessation pill Chantix just got a reprieve from the Food and Drug Administration: The Pfizer drug no longer needs to carry a black box warning label noting that users are at risk for ...